- Home
- IMMX vs YOTA Comparison
IMMX vs YOTA Comparison
Compare IMMX & YOTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- YOTA
- Stock Information
- Founded
- IMMX 2014
- YOTA 2021
- Country
- IMMX United States
- YOTA United States
- Employees
- IMMX N/A
- YOTA N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- YOTA Farming/Seeds/Milling
- Sector
- IMMX Health Care
- YOTA Consumer Staples
- Exchange
- IMMX Nasdaq
- YOTA Nasdaq
- Market Cap
- IMMX 51.1M
- YOTA 43.6M
- IPO Year
- IMMX 2021
- YOTA 2022
- Fundamental
- Price
- IMMX $1.51
- YOTA $11.12
- Analyst Decision
- IMMX Strong Buy
- YOTA
- Analyst Count
- IMMX 1
- YOTA 0
- Target Price
- IMMX $7.00
- YOTA N/A
- AVG Volume (30 Days)
- IMMX 139.0K
- YOTA 985.0
- Earning Date
- IMMX 11-11-2024
- YOTA 01-01-0001
- Dividend Yield
- IMMX N/A
- YOTA N/A
- EPS Growth
- IMMX N/A
- YOTA 674.22
- EPS
- IMMX N/A
- YOTA 0.28
- Revenue
- IMMX N/A
- YOTA N/A
- Revenue This Year
- IMMX N/A
- YOTA N/A
- Revenue Next Year
- IMMX $200.00
- YOTA N/A
- P/E Ratio
- IMMX N/A
- YOTA $39.83
- Revenue Growth
- IMMX N/A
- YOTA N/A
- 52 Week Low
- IMMX $1.26
- YOTA $10.35
- 52 Week High
- IMMX $7.75
- YOTA $15.49
- Technical
- Relative Strength Index (RSI)
- IMMX 40.19
- YOTA 58.35
- Support Level
- IMMX $1.26
- YOTA $11.09
- Resistance Level
- IMMX $1.80
- YOTA $11.13
- Average True Range (ATR)
- IMMX 0.15
- YOTA 0.00
- MACD
- IMMX 0.00
- YOTA 0.01
- Stochastic Oscillator
- IMMX 41.38
- YOTA 91.43
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About YOTA Yotta Acquisition Corporation
Yotta Acquisition Corp is a shell company.